Mira Pharmaceuticals Ketamir-2 PTSD Results
- MIRA Pharmaceuticals announced encouraging research findings on its drug candidate, Ketamir-2, demonstrating its ability to restore normal behavior in stressed animals exhibiting symptoms mirroring post-traumatic stress syndrome (SSPT).
- Currently in phase 1 clinical trials for the treatment of neuropathic pain,Ketamir-2 is now being investigated for its broader potential in neuropsychiatric disorders,including SSPT.
- According to MIRA Pharmaceuticals CEO Erez Aminov,the research highlights the drug's potential for treating post-traumatic stress syndrome.
MIRA Pharmaceuticals Reports Positive Results for Ketamir-2 in PTSD-Like Symptoms
Table of Contents
Published September 16, 2025, at 12:02 PM
Ketamir-2 Shows Promise in Animal Models of Post-Traumatic Stress
MIRA Pharmaceuticals announced encouraging research findings on its drug candidate, Ketamir-2, demonstrating its ability to restore normal behavior in stressed animals exhibiting symptoms mirroring post-traumatic stress syndrome (SSPT). teh study,utilizing a unique prolonged stress model (SPS) on rats,revealed behavioral improvements following oral administration of Ketamir-2,suggesting a reversal of SSPT-type behaviors.
Current Trials and Potential Applications
Currently in phase 1 clinical trials for the treatment of neuropathic pain,Ketamir-2 is now being investigated for its broader potential in neuropsychiatric disorders,including SSPT. These findings support further exploration of the drug’s efficacy in treating a range of mental health conditions.
Future Collaborations and Therapeutic Gaps
According to MIRA Pharmaceuticals CEO Erez Aminov,the research highlights the drug’s potential for treating post-traumatic stress syndrome. The company is actively seeking collaborations with military and government organizations to address critical therapeutic gaps in this area. Regis Pierpont originally reported this data.